Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Current Leases (2019 - 2025)

Historic Current Leases for Regenxbio (RGNX) over the last 7 years, with Q3 2025 value amounting to $9.1 million.

  • Regenxbio's Current Leases rose 1752.59% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.1 million, marking a year-over-year increase of 1752.59%. This contributed to the annual value of $7.9 million for FY2024, which is 1179.97% up from last year.
  • As of Q3 2025, Regenxbio's Current Leases stood at $9.1 million, which was up 1752.59% from $8.0 million recorded in Q2 2025.
  • Regenxbio's Current Leases' 5-year high stood at $9.1 million during Q3 2025, with a 5-year trough of $1.3 million in Q3 2021.
  • In the last 5 years, Regenxbio's Current Leases had a median value of $6.3 million in 2023 and averaged $5.4 million.
  • Per our database at Business Quant, Regenxbio's Current Leases crashed by 6271.04% in 2021 and then soared by 24229.45% in 2022.
  • Regenxbio's Current Leases (Quarter) stood at $1.8 million in 2021, then surged by 242.29% to $6.0 million in 2022, then grew by 17.86% to $7.1 million in 2023, then rose by 11.8% to $7.9 million in 2024, then increased by 14.82% to $9.1 million in 2025.
  • Its last three reported values are $9.1 million in Q3 2025, $8.0 million for Q2 2025, and $7.9 million during Q1 2025.